Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CCR4 | P51679 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL943003 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM1AMAOAMAOBCCR1 | |
| SCHEMBL1039500 | 0.87 | CXCR4 (0.50) | SMN1; SMN2CXCR4NPSR1CCR4PDCD1LG2 | |
| SCHEMBL22564633 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM1AMAOAMAOBCCR1 | |
| SCHEMBL9777407 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM1AMAOAMAOBCCR1 | |
| SCHEMBL4550251 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM1AMAOAMAOBCCR1 | |
| SCHEMBL9777453 | 0.81 | SMN1; SMN2 (0.64) | SMN1; SMN2KDM1AMAOAMAOBCCR1 | |
| SCHEMBL21986550 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM1AMAOAMAOBCXCR4 | |
| SCHEMBL25376464 | 0.79 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM1AMAOAMAOBMEN1 | |
| SCHEMBL10483914 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM1AMAOAMAOBCCR1 | |
| SCHEMBL2258317 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM1AMAOAMAOBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341893-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2003-09-10 | — | — | EP | claimed |
| WO-2002048307-A1 | ENZYMATIC DETERGENT COMPOSITIONS | UNILEVER N.V. (NL) | 2002-06-20 | — | — | WO | claimed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| CN-101460453-B | Novel sulfonamide compounds | ACTELION PHARMACEUTICALS LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| US-8003654-B2 | N-glycinsulfonamide derivatives and uses as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-05 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| CN-1332942-C | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-22 | — | — | CN | disclosed |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-19 | — | — | US | disclosed |
| CN-1703397-A | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-11-30 | — | — | CN | disclosed |
| EP-1554239-A2 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | SMN1; SMN2 2677/4885KDM1A 4723/4885MAOA 2926/4885 |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | HCRTR2, HCRTR1, GIPR | SMN1; SMN2 1796/4885KDM1A 890/4885MAOA 291/4885 |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | SMN1; SMN2 3319/4885KDM1A 4385/4885MAOA 2686/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | SMN1; SMN2 3678/4885KDM1A 3392/4885MAOA 1687/4885 |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | HCRTR2, HCRTR1, NPSR1 | SMN1; SMN2 1760/4885KDM1A 1269/4885MAOA 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.